EAdjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

被引：223

作者：

Kris, Mark G. ^{[2
]}

Gaspar, Laurie E. ^{[5
]}

Chaft, Jamie E. ^{[2
]}

Kennedy, Erin B. ^{[1
]}

Azzoli, Christopher G. ^{[6
]}

Ellis, Peter M. ^{[10
]}

Lin, Steven H. ^{[7
]}

Pass, Harvey I. ^{[3
]}

Seth, Rahul ^{[4
]}

Shepherd, Frances A. ^{[11
]}

Spigel, David R. ^{[9
]}

Strawn, John R. ^{[8
]}

Ung, Yee C. ^{[12
]}

Weyant, Michael ^{[5
]}

机构：

[1] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA

[2] Mem Sloan Kettering Canc Ctr, Hauppauge, NY USA

[3] NYU, Langone Med Ctr, New York, NY USA

[4] Syracuse Univ, Upstate Med Ctr, Syracuse, NY USA

[5] Univ Colorado, Sch Med, Aurora, CO USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] MD Anderson Canc Ctr, Houston, TX USA

[8] Patient Representat, Houston, TX USA

[9] Sarah Cannon Canc Ctr, Nashville, TN USA

[10] Juravinski Canc Ctr, Hamilton Hlth Sci, Hamilton, ON, Canada

[11] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[12] Sunnybrook Reg Canc Ctr, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 25期

关键词：

TYROSINE KINASE INHIBITORS; POSTOPERATIVE RADIOTHERAPY; INTERNATIONAL ASSOCIATION; INDEPENDENT PREDICTOR; PROGNOSTIC MARKER; POOLED ANALYSIS; BAD-NEWS; CHEMOTHERAPY; ADENOCARCINOMA; CLASSIFICATION;

D O I：

10.1200/JCO.2017.72.4401

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected non-small-cell lung cancers. Methods ASCO convened an update panel and conducted a systematic review of the literature, investigating adjuvant therapy in resected non-small-cell lung cancers. Results The updated evidence base covered questions related to adjuvant systemic therapy and included a systematic review conducted by Cancer Care Ontario current to January 2016. A recent American Society for Radiation Oncology guideline and systematic review, previously endorsed by ASCO, was used as the basis for recommendations for adjuvant radiation therapy. An update of these systematic reviews and a search for studies related to radiation therapy found no additional randomized controlled trials. Recommendations Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with stage IIA, IIB, or IIIA disease who have undergone complete surgical resections. For individuals with stage IB, adjuvant cisplatin-based chemotherapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a medical oncologist, is recommended to assess benefits and risks of adjuvant chemotherapy for each patient. The guideline provides information on factors other than stage to consider when making a recommendation for adjuvant chemotherapy, including tumor size, histopathologic features, and genetic alterations. Adjuvant chemotherapy is not recommended for patients with stage IA disease. Adjuvant radiation therapy is not recommended for patients with resected stage I or II disease. In patients with stage IIIA N2 disease, adjuvant radiation therapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a radiation oncologist, is recommended to assess benefits and risks of adjuvant radiation therapy for each patient with N2 disease. (C) 2017 by American Society of Clinical Oncology

引用

页码：2960 / +

页数：17

共 79 条

[41] The New Histologic Classification of Lung Primary Adenocarcinoma Subtypes Is a Reliable Prognostic Marker and Identifies Tumors With Different Mutation Status [J].

Mansuet-Lupo, Audrey ;

Bobbio, Antonio ;

Blons, Helene ;

Becht, Etienne ;

Ouakrim, Hanane ;

Didelot, Audrey ;

Charpentier, Marie-Christine ;

Bain, Serge ;

Marmey, Beatrice ;

Bonjour, Patricia ;

Biton, Jerome ;

Cremer, Isabelle ;

Dieu-Nosjean, Marie-Caroline ;

Sautes-Fridman, Catherine ;

Regnard, Jean-Francois ;

Laurent-Puig, Pierre ;

Alifano, Marco ;

Damotte, Diane .

CHEST, 2014, 146 (03) :633-643

[42]

Mead H, 2008, RACIAL ETHNIC DISPAR

[43] Postoperative Radiotherapy is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes Results of an Analysis of the National Cancer Data Base [J].

Mikell, John L. ;

Gillespie, Theresa W. ;

Hall, William A. ;

Nickleach, Dana C. ;

Liu, Yuan ;

Lipscomb, Joseph ;

Ramalingam, Suresh S. ;

Rajpara, Raj S. ;

Force, Seth D. ;

Fernandez, Felix G. ;

Owonikoko, Taofeek K. ;

Pillai, Rathi N. ;

Khuri, Fadlo R. ;

Curran, Walter J. ;

Higgins, Kristin A. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (03) :462-471

[44] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].

Mok, Tony S. ;

Wu, Yi-Long ;

Thongprasert, Sumitra ;

Yang, Chih-Hsin ;

Chu, Da-Tong ;

Saijo, Nagahiro ;

Sunpaweravong, Patrapim ;

Han, Baohui ;

Margono, Benjamin ;

Ichinose, Yukito ;

Nishiwaki, Yutaka ;

Ohe, Yuichiro ;

Yang, Jin-Ji ;

Chewaskulyong, Busyamas ;

Jiang, Haiyi ;

Duffield, Emma L. ;

Watkins, Claire L. ;

Armour, Alison A. ;

Fukuoka, Masahiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957

[45] Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC [J].

Morgensztern, Daniel ;

Du, Lingling ;

Waqar, Saiama N. ;

Patel, Aalok ;

Samson, Pamela ;

Devarakonda, Siddhartha ;

Gao, Feng ;

Robinson, Cliff G. ;

Bradley, Jeffrey ;

Baggstrom, Maria ;

Masood, Ashiq ;

Govindan, Ramaswamy ;

Puri, Varun .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) :1729-1735

[46] Lymphatic invasion predicts survival in patients with early node-negative non-small cell lung cancer [J].

Nentwich, Michael F. ;

Bohn, Benjamin A. ;

Uzunoglu, Faik G. ;

Reeh, Matthias ;

Quaas, Alexander ;

Grob, Tobias J. ;

Perez, Daniel ;

Kutup, Asad ;

Bockhorn, Maximilian ;

Izbicki, Jakob R. ;

Vashist, Yogesh K. .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2013, 146 (04) :781-787

[47] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer [J].

Novello, Silvia .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) :3985-+

[48] DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy [J].

Olaussen, Ken A. ;

Dunant, Ariane ;

Fouret, Pierre ;

Brambilla, Elisabeth ;

Andre, Fabrice ;

Haddad, Vincent ;

Taranchon, Estelle ;

Filipits, Martin ;

Pirker, Robert ;

Popper, Helmut H. ;

Stahel, Rolf ;

Sabatier, Laure ;

Pignon, Jean-Pierre ;

Tursz, Thomas ;

Le Chevalier, Thierry ;

Soria, Jean-Charles .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (10) :983-991

[49] Population-based validation of the prognostic model ADJUVANT! for early breast cancer [J].

Olivotto, IA ;

Bajdik, CD ;

Ravdin, PM ;

Speers, CH ;

Coldman, AJ ;

Norris, BD ;

Davis, GJ ;

Chia, SK ;

Gelmon, KA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2716-2725

[50] Adjuvant Carboplatin-based Chemotherapy in Resected Stage IIIA-N2 Non-small Cell Lung Cancer [J].

Ou, Wei ;

Sun, Hai-bo ;

Ye, Xiong ;

Zhang, Bin-bin ;

Yang, Hua ;

Fang, Qin ;

Li, Pan ;

Wang, Si-yu .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (07) :1033-1041

← 1 2 3 4 5 6 7 8 →